Get the Stockscreener App
9.62
2.97%
-0.31
Biohaven Ltd stock is traded at $9.62, with a volume of 135.46K.
It is down -2.97% in the last 24 hours and up +0.89% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$9.93
Open:
$9.96
24h Volume:
135.46K
Relative Volume:
0.04
Market Cap:
$1.28B
Revenue:
-
Net Income/Loss:
$-766.97M
P/E Ratio:
-1.2559
EPS:
-7.66
Net Cash Flow:
$-646.43M
1W Performance:
-17.23%
1M Performance:
+0.89%
6M Performance:
-34.14%
1Y Performance:
-75.21%
1-Day Range:
$9.61
$10.02
1-Week Range:
$9.57
$11.72
52-Week Range:
$7.48
$44.28
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
9.6275 | 1.32B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.91 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.61 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.65 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.52 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.23 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Biohaven Ltd. (NYSE:BHVN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Biohaven (NYSE:BHVN) Trading Down 8%Here's What Happened - MarketBeat
Biohaven (BHVN) Is Down 6.1% After Ending BHV-7000 Depression Trial To Refocus On Epilepsy And Obesity - simplywall.st
The Bull Case For Biohaven (BHVN) Could Change Following BHV-7000 MDD Trial Halt And R&D Pivot - Yahoo! Finance Canada
Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Biohaven (BHVN) Earnings Date and Reports 2026 - MarketBeat
Risk Check: Why Biohaven Ltd stock attracts global investorsLong Setup & Fast Exit and Entry Strategy Plans - moha.gov.vn
Breakout Move: Why Biohaven Ltd stock attracts global investorsJuly 2025 Catalysts & Low Drawdown Momentum Ideas - moha.gov.vn
Wall Street analysts predict an 88.57% upside in Biohaven Ltd. (BHVN): Here's what you should know - MSN
Biohaven reports Phase 2 depression trial results - Indian Pharma Post
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
(BHVN) Risk Channels and Responsive Allocation - Stock Traders Daily
Biohaven (NYSE:BHVN) Trading 3.6% HigherHere's What Happened - MarketBeat
Analysts Conflicted on These Healthcare Names: Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven Shares Rally as Promising Cancer Data Unveiled - StocksToTrade
Biohaven Reports Promising Results for Cancer Treatment, Faces Setback in Depression Therapy - StocksToTrade
Biohaven’s BHV-1510 Promising Cancer Data Fuels Market Anticipation - timothysykes.com
Biohaven Emerges Strong Amid Promising Cancer Drug Data - timothysykes.com
Key facts: Biohaven Ltd. develops BHV-7000 for epilepsy; J.P. Morgan reports poor trial results - TradingView — Track All Markets
What's Going On With Biohaven Stock Friday? - Benzinga
Biohaven (NYSE:BHVN) Shares Gap DownWhat's Next? - MarketBeat
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology - FinancialContent
Biohaven Stock Gaps Lower on Failed Phase 2 Drug Trial - Schaeffer's Investment Research
US Stocks Mixed; Biohaven Shares Fall - Sahm
Watch Nvidia Up on AI Licensing Deal, Biohaven Down on Study Results, Coforge Up - Bloomberg.com
Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED) - Benzinga
Cautiously Bullish After Biohaven’s Cash Runway And Dilution Risk Rise (NYSE:BHVN) - Seeking Alpha
Stock Movers: Nvidia, Coforge, Biohaven - Bloomberg.com
Stifel reiterates Buy rating on Xenon Pharmaceuticals stock amid competitor setback - Investing.com
Biohaven Misses The Mark In Depression Trial, Stock Falls - Benzinga
H.C. Wainwright maintains Biohaven stock at Neutral after MDD trial failure - Investing.com Nigeria
Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Biohaven downgraded to Market Perform from Outperform at Bernstein - MSN
Biohaven stock defended despite trial setback (BHVN:NYSE) - Seeking Alpha
Stock market today: Dow Jones, S&P 500 futures slip after Christmas Day—Nvidia, Sobr Safe, Biohaven in focus - MSN
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus - Sahm
Why Davis Commodities Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Nvidia, Sobr Safe And 3 Stocks To Watch Heading Into Friday - Benzinga
Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER) - The Globe and Mail
Biohaven (BHVN) Valuation Check After BHV-1510 Cancer Data and BHV-7000 Pipeline Shift - simplywall.st
Biohaven Shares Dive: Time to Reflect? - StocksToTrade
Biohaven’s depression drug misses primary endpoint in Phase 2 study By Investing.com - Investing.com Nigeria
Biohaven's depression drug fails mid-stage trial, shares fall - marketscreener.com
Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 — Retail Eyes Epilepsy And Obesity Catalysts - Stocktwits
Biohaven Provides Update From Phase 2 Proof-of-Concept Study wit - GuruFocus
Biohaven (NYSE:BHVN) Stock Price Down 13%What's Next? - MarketBeat
Biohaven’s depression drug misses primary endpoint in Phase 2 study - Investing.com India
Biohaven stock falls after depression drug misses primary endpoint By Investing.com - Investing.com Nigeria
Biohaven falls as depression candidate fails in phase 2 - Seeking Alpha
Biohaven stock falls after depression drug misses primary endpoint - Investing.com
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):